Absci Corporation (ABSI)

Market Cap	450.00M
Revenue (ttm)	4.14M
Net Income (ttm)	-113.30M
Shares Out	144.23M
EPS (ttm)	-0.94
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,460,716
Open	2.835
Previous Close	2.970
Day's Range	2.800 - 3.400
52-Week Range	2.010 - 6.330
Beta	2.04
Analysts	Strong Buy
Price Target	8.08 (+158.97%)
Earnings Date	Aug 12, 2025

About ABSI

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to design differentiated antibody therapeutics. Its preclinical development programs include ABS-101 for the treatment of inflammatory bowel disease; ABS-201 for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 22, 2021
• Employees: 157
• Stock Exchange: NASDAQ
• Ticker Symbol: ABSI
• Website: https://www.absci.com

Financial Performance

In 2024, Absci's revenue was $4.53 million, a decrease of -20.71% compared to the previous year's $5.72 million. Losses were -$103.11 million, -6.75% less than in 2023.

Analyst Forecast

According to 5 analysts, the average rating for ABSI stock is "Strong Buy." The 12-month stock price target is $8.08, which is an increase of 158.97% from the latest price.

Price Target

$8.08

(158.97% upside)

Analyst Consensus: Strong Buy